Investor
Relations

• Operate in clients' revenue-generating engine: Commercial & Med teams behind launches, brands & growth
• Sit on growth-side budgets, not IT cost budgets; less exposed to cost-cutting cycles
• Productivity-benefit gets redeployed as increased volume: personalized content and more channels

• With over 27 years of experience in life sciences, we are deeply integrated in client workflows
• Manage critical workflows requiring high degree of domain expertise and regulatory compliance
• Judgment-intensive work where GenAI compounds domain knowledge rather than replacing it

• Pharma companies face complexity explosion (content volume & regulatory compliance) & fragmented non-standardized models resulting in efforts to centralize operations
• Our AI-enabled solutions engage at enterprise level (not brand-by-brand) to re-engineer & re-imagine end-to-end processes, thus accelerating this transformation & taking wallet share from incumbents
• GenAI price deflation pressures large incumbents but provides growth headroom for us at our current scale

• Global delivery model with multi-geography governance & standardization generating productivity at scale
• Majority revenue is outcome-aligned — paid for work delivered and value created
• Efficiency gains flow to the bottom line, creating incentive to adopt and scale newer technologies faster

*Revenue from Enterprise Contracts